Evaluation of Immunological Persistence Following 3-dose Priming With GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine in Study NCT00808444 and Safety and Immunogenicity Following a Booster Dose of the Same Vaccine
Latest Information Update: 28 Jun 2023
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Hib-DTaP-poliovirus vaccine
- Indications Otitis media; Pneumococcal infections; Pneumonia
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 25 Oct 2016 New trial record